Mesoblast reported that 21 of the first 25 pediatric patients treated with its mesenchymal‑stromal‑cell therapy Ryoncil achieved 28‑day survival, an 84 % rate that matches the pivotal trial outcome. The data were collected from 45 U.S. transplant centers that have adopted Ryoncil since its commercial launch in March 2025, underscoring the product’s rapid uptake in the real‑world setting.
The 84 % survival figure is a key clinical validation that reinforces Ryoncil’s value proposition to payers and clinicians. By demonstrating that real‑world outcomes mirror the controlled‑trial results, Mesoblast strengthens its case for continued reimbursement coverage and supports the company’s plan to pursue a pivotal trial for adult steroid‑refractory acute graft‑versus‑host disease (SR‑aGvHD) this quarter.
Ryoncil’s commercial momentum is further evidenced by the expansion of payer coverage to more than 260 million U.S. lives, including the issuance of a specific HCPCS J‑code on October 1 2025. The company’s 45 onboarded centers represent 94 % of U.S. transplant volume, and the target of 64 centers is already within reach. This broad access base is expected to accelerate sales growth, which rose 60 % to $35.1 million in the quarter ended December 31 2025.
Management highlighted the importance of early treatment initiation. Dr. Silviu Itescu noted that “excellent early survival rates” are achieved when Ryoncil is administered promptly after steroid resistance, emphasizing that timely physician referral is critical to maximizing patient outcomes.
The real‑world data also provide a strong evidence base for the company’s strategic expansion into the adult SR‑aGvHD market, which is roughly three times larger than the pediatric segment. By aligning clinical efficacy with commercial traction, Mesoblast positions Ryoncil to capture a significant share of this high‑value market.
Analysts and investors responded positively to the announcement. Market reaction was driven by the confirmation of clinical efficacy, the robust sales growth, and the clear path to label expansion, all of which reinforce confidence in Mesoblast’s growth trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.